Aceso Life Science Group

474

The current Aceso Life Science Group (474) market capitalization is approximately HK$826.76M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Aceso Life Science Group's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:55 PM Eastern Time

In the most recently reported quarter, Aceso Life Science Group (474) generated HK$-4.50M in revenue, representing a -123.08% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 3:07 AM Eastern Time

In the most recently reported fiscal year, Aceso Life Science Group (474) generated net income of HK$-0.90B, compared with HK$-0.46B in the prior fiscal year, representing a -93.72% year over year change. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 3:07 AM Eastern Time

As of the most recent reporting period, the company's debt-to-equity ratio stands at 3.32x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: January 1, 2026 at 3:07 AM Eastern Time

Based on the latest available data, Aceso Life Science Group (474) is currently trading at a last twelve months (LTM) P/E ratio of -2.15x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: January 1, 2026 at 3:07 AM Eastern Time

In the most recently reported quarter, Aceso Life Science Group (474) revenue was HK$-4.50M. Earnings per share (EPS) for the quarter were HK$0.03. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 3:07 AM Eastern Time

Aceso Life Science Group (474) does not currently pay a dividend. Over the last twelve months (LTM), the company paid HK$0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 3:07 AM Eastern Time

Based on the latest available analyst coverage, Aceso Life Science Group (474) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 3:07 AM Eastern Time

Like other publicly traded stocks, Aceso Life Science Group (474) shares are bought and sold on stock exchanges such as SEHK and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Aceso Life Science Group (474) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 474 to your watchlist.

Aceso Life Science Group trades under the ticker symbol 474 on the SEHK stock exchange. The ticker 474 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Aceso Life Science Group (474) employs approximately 41 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: December 31, 2025 at 11:55 PM Eastern Time

Aceso Life Science Group (474) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Aceso Life Science Group (474) stock peers based on overlapping products, services, and competitive dynamics:Hao Wen Holdings (8019)K Cash Corporation (2483)ValueMax Group (T6I)Premium Group (7199)Yixin Group (2858)Upbest Group (335)J Trust (8508)AEON Financial Service (8570) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Aceso Life Science Group.